Pathological complete response to neoadjuvant lorlatinib in a patient with unresectable ALK-Positive locally advanced non-small cell lung cancer: A case report

Pathological complete response to neoadjuvant lorlatinib in a patient with unresectable ALK-Positive locally advanced non-small cell lung cancer: A case report

Anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK-TKIs) have demonstrated substantial effectiveness in individuals with advanced ALK-positive non-small cell lung cancer (NSCLC). However, the controversy over using ALK-TKIs for neoadjuvant therapy in ALK-positive NSCLC has not been fully exp...

Full description

Bibliographic Details
Main Authors: Ruiqi Chen, Lilan Zhao, Juan Zhang, Lingwen Guo, Zhizhong Chen, Xiaojie Pan, Wenshu Chen
Format: Article
Language:English
Published: Elsevier 2023-11-01
Series:Heliyon
Subjects:
NSCLC
Lorlatinib
Neoadjuvant targeted therapy
ALK
pCR
Online Access:http://www.sciencedirect.com/science/article/pii/S240584402308790X

Internet

http://www.sciencedirect.com/science/article/pii/S240584402308790X

Similar Items